South Africa: Jacob Modumoh OBP Suspension over Vaccine Prices

• Dr. Jacob Modumoh, Acting CEO of Onderstepoort Biological Products, was placed on precautionary suspension over alleged misconduct regarding foot-and-mouth disease vaccine pricing.
• Agriculture Minister Willie Aucamp initiated the suspension, emphasizing that state-owned entities should not profit excessively from critical public health crises.
• The suspension is precautionary, pending an independent investigation into the pricing claims, and does not imply guilt.
• The controversy involves the use of taxpayer money for vaccine procurement during South Africa's largest FMD outbreak, not direct overcharging of farmers.
• An advocacy group, FMD Response SA, has called for an independent review of the country's FMD testing system due to concentrated functions within related entities.

Minister Aucamp stressed that as a government entity, Onderstepoort Biological Products must prioritize public interest over profit, particularly during a national crisis impacting farmers.

Dr. Jacob Modumoh, who served as the Acting Chief Executive Officer of Onderstepoort Biological Products (OBP), has been placed on precautionary suspension following allegations of serious misconduct. These claims specifically relate to the pricing of crucial foot-and-mouth disease (FMD) vaccines during a significant outbreak. The suspension was confirmed by Agriculture Minister Willie Aucamp after he convened an urgent meeting with the OBP board on Friday, September 4th.

During this meeting, Minister Aucamp presented information concerning the allegations against Dr. Modumoh to the board members. Subsequently, the board informed Dr. Modumoh of its intention to suspend him. In adherence to company policy, he was granted a five-day period to provide a rationale against the proposed suspension. Minister Aucamp clarified that the suspension would remain in effect, pending the outcome of an independent investigation, should Dr. Modumoh's explanations prove insufficient to alter the board's decision.

It is important to note that Minister Aucamp explicitly stated that this precautionary suspension does not constitute a finding of guilt regarding any wrongdoing on Dr. Modumoh's part. The claims themselves have yet to undergo an independent investigation, underscoring the preliminary nature of the action taken. This development places the Jacob Modumoh OBP suspension vaccine prices controversy squarely in the public spotlight.

The controversy surrounding FMD vaccine prices emerges at a critical juncture for South Africa's livestock sector, which is currently grappling with what Minister Aucamp has described as the most extensive foot-and-mouth disease outbreak in the nation's history. Farmers are already enduring substantial financial strain as they strive to safeguard their animals and livelihoods against the disease. In this context, Minister Aucamp underscored the fundamental obligation of Onderstepoort Biological Products, as a state-owned enterprise, to serve the public interest.

He asserted that OBP should not seek to generate excessive profits from vaccines that are essential for combating the outbreak. Minister Aucamp explicitly stated that there should be no exorbitant markup on the sale of FMD vaccines, particularly given the heavy financial burden already borne by farmers. He further emphasized the government's responsibility to ensure that these vital vaccines are procured and supplied as affordably and efficiently as possible.

Minister Aucamp also pledged rigorous oversight of all public entities falling under his department's purview. He articulated a clear expectation for the department, its entities, and their respective boards to operate ethically and uphold the highest standards, indicating that anything less would be unacceptable. This stance highlights the government's commitment to public procurement ethics ZA and addressing potential South Africa state-owned enterprise misconduct.

The organization FMD Response SA lauded Minister Aucamp's intervention, drawing attention to a crucial aspect often overlooked in discussions about vaccine pricing. According to the organization, the vaccines central to the allegations were acquired for the national response using public funds, meaning taxpayer money. Andrew Morphew, a spokesperson for FMD Response SA, clarified that this situation was not a case of farmers being overcharged directly, but rather the Department of Agriculture remunerating a state-owned company with public resources.

Morphew commended the Minister for fulfilling the oversight role expected of his office. Historically, the supply of FMD vaccines operated through a single, centralized channel. However, a new agreement implemented in July introduced a significant change, allowing both farmers and veterinarians to purchase vaccines directly, thereby diversifying the supply chain.

Building on the current scrutiny, FMD Response SA is advocating for an even broader examination, specifically calling for an independent assessment of South Africa's foot-and-mouth disease testing system. The organization acknowledges that Onderstepoort Biological Products and the Agricultural Research Council's Onderstepoort Veterinary Institute are distinct entities. However, it has voiced concerns regarding the continued concentration of several critical components of the country's disease response within a single operational channel.

FMD Response SA highlighted that this institute is responsible for confirming outbreaks, conducting necessary testing, advising the government on appropriate vaccine usage, and also manufactures its own vaccine for the national response. This perceived consolidation of functions raises questions about potential conflicts of interest or inefficiencies, prompting the call for an independent review to ensure transparency and effectiveness in the nation's disease management protocols.

Compliance officers and legal counsel advising state-owned enterprises in South Africa should review their procurement and pricing policies to ensure ethical conduct and prevent allegations of excessive profit-making, particularly during national crises, as government oversight is intensifying and could lead to similar executive suspensions and investigations.

Source: Original reporting via industry sources.